Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $330

Benzinga · 2d ago
Piper Sandler analyst David Amsellem maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $310 to $330.